The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 Update

Journal of Clinical Psychiatry

Volumn 65, Issue 4, 2004, Pages 500-508

  Miller, Alexander L ^a,b,s   Hall, Catherine S ^a   Buchanan, Robert W ^c   Buckley, Peter F ^d   Chiles, John A ^e   Conley, Robert R ^c   Crismon, M Lynn ^f,g   Ereshefsky, Larry ^a,b,f   Essock, Susan M ^h,i   Finnerty, Molly ^j   Marder, Stephen R ^k   Miller, Del D ^l   McEvoy, Joseph P ^m   Rush, A John ⁿ   Saeed, Sy A ^o   Schooler, Nina R ^p   Shon, Steven P ^g   Stroup, Scott ^q   Tarin Godoy, Bernardo ^r  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b San Antonio State Hospital   (United States)

^c MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^g Texas Department of Mental Health and Mental Retardation   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

ⁱ Education   (United States)

^j New York State Office of Alcoholism   (United States)

^k VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^l UNIVERSITY OF IOWA   (United States)

^m DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^o UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^p ZUCKER HILLSIDE HOSPITAL   (United States)

^q UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^r El Paso Community Mental Health and Mental Retardation Center   (United States)

^s Mays Cancer Center at UT Health San Antonio   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE; THIAZOLE DERIVATIVE; ZIPRASIDONE;

ALGORITHM; AMBULATORY CARE; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DECISION TREE; DRUG ADMINISTRATION; DRUG COMBINATION; HUMAN; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PSYCHOLOGY; SCHIZOPHRENIA; STANDARD; TREATMENT OUTCOME; UNITED STATES;

ALGORITHMS; AMBULATORY CARE; AMBULATORY CARE FACILITIES; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DECISION TREES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; PIPERAZINES; PRACTICE GUIDELINES; QUINOLONES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TEXAS; THIAZOLES; TREATMENT OUTCOME;

EID: 2442473932     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v65n0408     Document Type: Review

References (74)

1. Gilbert DA, Altshuler KZ, Rago WV, et al. Texas Medication Algorithm Project: definitions, rationale, and methods to develop medication algorithms. J Clin Psychiatry 1998;59:345-351 (Pubitemid 28373100)
2. Rush AJ, Crismon ML, Toprac MG, et al. Consensus guidelines in the treatment of major depressive disorder. J Clin Psychiatry 1998;59(suppl 20):73-84 (Pubitemid 29001831)
3. Chiles JA, Miller AL, Crismon ML, et al. The Texas Medication Algorithm Project: development and implementation of the schizophrenia algorithm. Psychiatr Serv 1999;50:69-74 (Pubitemid 29035359)
4. Crismon ML, Trivedi MH, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Major Depressive Disorder. J Clin Psychiatry 1999;60:142-156 (Pubitemid 29168686)
5. Rush AJ, Rago WV, Crismon ML, et al. Medication treatment for the severely and persistently mentally ill: the Texas Medication Algorithm Project. J Clin Psychiatry 1999;60:284-291 (Pubitemid 29246891)
6. Miller AL, Chiles JA, Chiles JK, et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999;60:649-657 (Pubitemid 29503644)
7. Kashner TM, Rush AJ, Altshuler KZ. Measuring costs of guideline-driven mental health care: the Texas Medication Algorithm Project. J Ment Health Policy Econ 1999; 2:111-121
8. Suppes T, Swann AC, Dennehy EB, et al. Texas Medication Algorithm Project: development and feasibility testing of a treatment algorithm for patients with bipolar disorder. J Clin Psychiatry 2001;62:439-447 (Pubitemid 32717877)
9. Kashner TM, Carmody TJ, Suppes T, et al. Catching-up on health outcomes: the Texas Medication Algorithm Project. Health Serv Res 2003;28:311-331 (Pubitemid 36373311)
10. Rush AJ, Crismon ML, Kashner TM, et al for the TMAP Research Group. Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry 2003;64:357-369
11. Suppes T, Rush AJ, Dennehy EB, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): clinical results for patients with a history of mania. J Clin Psychiatry 2003;64:370-382 (Pubitemid 36547278)
12. Frances A, Docherty JP, Kahn DA. Expert Consensus Guidelines Series: treatment of schizophrenia. J Clin Psychiatry 1996;57(suppl 12B):5-58
13. Lehman AF, Thompson JW, Dixon LB, et al. Schizophrenia: treatment outcomes research: editors' introduction. Schizophr Bull 1995;21:561-566
14. Clinical Practice Guideline Number 5: Depression in Primary Care, vol.2. Treatment of Major Depression. Rockville, Md: US Dept Health Human Services, Agency for Health Care Policy and Research; 1993. AHCPR publication 93-0550
15. Geodon [package insert]. New York, NY: Pfizer Inc; 2001
16. Pfizer Inc. FDA Psychopharmacological Drugs Advisory Committee Briefing Document for Zeldox Capsules (Ziprasidone HCl); July 19, 2000. Available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1a.pdf. Accessed March 15, 2004
17. Glassman AH, Bigger JT. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry 2001;158:1774-1782 (Pubitemid 33054769)
18. Weiden PJ, Iqbal N, Mendelowitz AJ, et al. Best clinical practice with ziprasidone: update after one year of experience. J Psychiatr Pract 2002;8:81-98
19. Goff DC, Posever TA, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304 (Pubitemid 28353872)
20. Simpson GM, Romano SJ, Horne RL, et al. Ziprasidone vs olanzapine in schizophrenia: results of a double blind trial. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
21. Weiden PJ, Simpson GM, Potkin SG, et al. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J Clin Psychiatry 2003;64:580-588 (Pubitemid 36618289)
22. Allison DB, Mentore JL, Heo M. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156:1686-1696 (Pubitemid 29517559)
23. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159:561-566 (Pubitemid 34274937)
24. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783 (Pubitemid 28496795)
25. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychcopharmacol 1998;21:369-374 (Pubitemid 32673025)
26. Geddes J, Freemantle N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-1376
27. Kapur S, Remington G. Patients value the lower incidence of extrapyramidal side effects [editorial]. BMJ 2000;321:1360-1361
28. Prior C, Clements J, Rowett M. Atypical antipsychotics in the treatment of schizophrenia [letter]. BMJ 2001;322:924-925 (Pubitemid 32324323)
29. Duggins R, Phinds D, Hall W. Atypical antipsychotics in the treatment of schizophrenia: cost is a crucial issue [letter]. BMJ 2001;322:926 (Pubitemid 32324323)
30. Anderson I. Atypical antipsychotics in the treatment of schizophrenia: users' views are important [letter]. BMJ 2001;322:926 (Pubitemid 32324323)
31. Rowsell R, Link C, Donoghue J. Atypical antipsychotics in the treatment of schizophrenia: validity of dropout rates as proxy measure of tolerability is unknown [letter]. BMJ 2001;322:925
32. Adams CE, Duggan L. Atypical antipsychotics in the treatment of schizophrenia: paper corrupts concept of evidence based medicine [letter]. BMJ 2001;322:927-928
33. Lee S. Atypical antipsychotics in the treatment of schizophrenia: "informed relationship between doctor and patient" does not exist in many parts of the world [letter]. BMJ 2001;322:925-926
34. Kerwin R. Atypical antipsychotics in the treatment of schizophrenia [letter]. BMJ 2001;322:926-927 (Pubitemid 32324323)
35. Taylor D. Atypical antipsychotics in the treatment of schizophrenia: pragmatic considerations are important when considering which drug to prescribe [letter]. BMJ 2001;322:927-928
36. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68 (Pubitemid 29023554)
37. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996;57(suppl 9):35-40 (Pubitemid 26327755)
38. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison versus chlorpromazine/ benztropine. Arch Gen Psychiatry 1988;45:789-796 (Pubitemid 18222922)
39. Marder SR, Essock SM, Miller AL, et al. The Mount Sinai Conference on the pharmacotherapy of schizophrenia. Schizophr Bull 2002;38:105-109 (Pubitemid 34534746)
40. Citrome L, Bilder R, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiatr Pract 2002;8:205-215
41. Buckley P, Miller AL, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull 2001;27:615-628 (Pubitemid 34093248)
42. Umbricht DS, Wirshing WC, Wirshing DA, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63:420-424 (Pubitemid 34507220)
43. Lieberman JA, Safferman AZ, Pollack S, et al. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 1994;151:1744-1752 (Pubitemid 24370894)
44. Meltzer HY, Alphs LD, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003;60:82-91 (Pubitemid 36070868)
45. Glazer WM, Dickson RA. Clozapine reduces violence and persistent aggression in schizophrenia. J Clin Psychiatry 1998;59(suppl 3):8-14 (Pubitemid 28196364)
46. Chiles JA, Davidson P, McBride D. Effects of clozapine on the use of seclusion and restraint. Hosp Community Psychiatry 1994;45:269-271
47. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-573 (Pubitemid 27527329)
48. Mowerman S, Siris SG. Adjunctive loxapine in a clozapine-resistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996;8:193-197 (Pubitemid 27033711)
49. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-397 (Pubitemid 26321990)
50. Friedman JH, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997;42:522-523 (Pubitemid 27394621)
51. Chong S-A, Remington G. Clozapine augmentation: safety and efficacy. Schizophr Bull 2000;26:421-440 (Pubitemid 30423219)
52. Benatov R, Sirota P, Megged S. Neuroleptic-resistant schizophrenia treated with clozapine and ECT. Convuls Ther 1996;12:117-121 (Pubitemid 26162470)
53. Bhatia SC, Bhatia SK, Gupta S. Concurrent administration of clozapine and ECT: a successful therapeutic strategy for a patient with treatment-resistant schizophrenia. J ECT 1998;14:280-283 (Pubitemid 29003841)
54. Kales HD, Dequardo JR, Tandon R. Combined electroconvulsive therapy and clozapine in treatment-resistant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:547-556 (Pubitemid 29274223)
55. James DV, Gray NS. Elective combined electroconvulsive and clozapine therapy. Int Clin Psychopharmacol 1999;14:69-72 (Pubitemid 29149864)
56. Miller AL, Craig CS. Combination antipsychotics: pros, cons, and questions. Schizophr Bull 2002;28:105-109 (Pubitemid 34534754)
57. Weiden PJ, Casey D. "Polypharmacy": combining antipsychotic medications in the treatment of schizophrenia. J Prac Psychiatry Behav Health 1999;5:229-233
58. Tran PV, Hamilton SH, Funtz AJ. Double-blind comparison and olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-418 (Pubitemid 27414397)
59. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158:765-774 (Pubitemid 32429846)
60. Casey DE, Carson WH, Saha AR, et al. Aripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 2003;166:391-399
61. Shiovitz TM, Welke TL, Tigel PD, et al. Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. Schizophr Bull 1996;22:591-595 (Pubitemid 26389405)
62. Malhotra S, Franco K, Tomford JW, et al. Polyserositis, acute withdrawal, and relapse after abrupt clozapine discontinuation. Psychosomatics 2002;43:418-420
63. Bowles TM, Levin GM. Aripiprazole: a new atypical antipsychotic drug. Ann Pharmacother 2003;37:687-694 (Pubitemid 36523066)
64. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: overview of phase II results [poster]. Presented at the 36th annual meeting of the American College of Neuropsychopharmacology; December 8-12, 1997; Waikoloa, Hawaii
65. Daniel DG, Saha AR, Ingenito GG, et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result [abstract]. Int J Neuropsychopharmacol 2000;3:S157
66. Lieberman JA, Carson WH, Saha AR, et al. Meta-analysis of the efficacy of aripiprazole in schizophrenia. Presented at the 23rd Congress of the Collegium Internationale Neuro-Psychopharmacologicum; June 23-27, 2002; Montreal, Canada
67. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-771
68. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-690 (Pubitemid 36818630)
69. Carson WH, Pigott T, Saha AR, et al. Aripiprazole vs. placebo in the treatment of stable, chronic schizophrenia [poster]. Presented at the 42nd annual meeting of the New Clinical Drug Evaluation Unit; June 10-13, 2002; Boca Raton, Fla
70. Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-1056 (Pubitemid 37158250)
71. Marcus R, Gharbia NA, Kujawa MJ, et al. Aripiprazole vs. placebo in the treatment of stable, chronic schizophrenia [poster]. Presented at the 2002 annual meeting of the American College of Clinical Pharmacy; October 20-23, 2002; Albuquerque, NM
72. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-136 (Pubitemid 36513927)
73. Fujikawa M, Nagashima M, Inoue T, et al. Partial agonistic effects of OPC-14597, a potential antipsychotic agent, on yawning behavior in rats. Pharmacol Biochem Behav 1996;53:903-909 (Pubitemid 26116144)
74. Crismon ML, DeLeon A, Miller AL. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits? Ann Pharmacother 2003;37:738-740